Smith Group Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Smith Group Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-42,700	Closed	-$5.14M	–	162
2024 Q1	$5.14M	Sell	42,700 -20,270	-32%	-$2.48M	0.29%	78
2023 Q4	$7.75M	Buy	+62,970	New	+$7.86M	0.45%	71
2020 Q2	–	Sell	-79,360	Closed	-$7.92M	–	331
2020 Q1	$7.92M	Sell	79,360 -19,440	-20%	-$2.51M	0.43%	61
2019 Q4	$14.7M	Sell	98,800 -52,700	-35%	-$7.17M	0.62%	58
2019 Q3	$19.4M	Sell	151,500 -2,470	-2%	-$331K	0.68%	59
2019 Q2	$21.9M	Buy	+153,970	New	+$20.7M	0.74%	53
2014 Q2	–	Sell	-87,000	Closed	-$12.1M	–	432
2014 Q1	$12.1M	Buy	+87,000	New	+$13.1M	0.46%	78
2013 Q4	–	Sell	-50,176	Closed	-$4.62M	–	413
2013 Q3	$4.62M	Sell	50,176 -12,876	-20%	-$1.04M	0.19%	93
2013 Q2	$4.33M	Buy	+63,052	New	+$3.85M	0.19%	105

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Smith Group Asset Management's JAZZ Position: Q2 2024 in Review

Smith Group Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 42,700 shares — an estimated $5.14M sold.

Smith Group Asset Management first reported a position in JAZZ in Q2 2013 and held it in 9 quarters. The position peaked at $21.9M in Q2 2019. 456 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Smith Group Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Smith Group Asset Management sold 42,700 Jazz Pharmaceuticals shares in Q2 2024, an estimated $5.14M.
Smith Group Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Smith Group Asset Management's Jazz Pharmaceuticals position peaked at $21.9M in Q2 2019.
456 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Smith Group Asset Management's 13F filing for Q2 2024, filed 31 Jul 2024.